Clostridium-Derived p-Cresyl Metabolites Induce Inflammation and Apoptosis in Biliary Epithelial Cells Authors: Haiyan Yu, Haiyan Fu, Jiamin Xu, Yina Yang, Xin Ai, Rongfang Tu, Weimin Bao, Yingmei Tang Published: 2026 ABSTRACT ObjectivePrimary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease, and the effects of p-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG) in PBC remain unclear. This study aimed to evaluate the pro-apoptotic and pro-inflammatory effects of PCS and PCG.MethodsHuman intrahepatic biliary epithelial cells (HIBEpiCs) were treated with PCS or PCG, and apoptosis was assessed by flow cytometry. Female C57BL/6 mice received intraperitoneal PCS or PCG. Liver inflammation was evaluated by H&E staining, apoptosis-related proteins (caspase-3, Bax, Bcl-2) by Western blotting, and serum TGF-β and IFN-γ by ELISA.ResultsPCS and PCG increased apoptosis in HIBEpiCs. In vivo, PCS and PCG treated mice displayed portal lymphocytic infiltration and elevated serum IFN-γ and TGF-β. Hepatic caspase-3 and Bax were upregulated, whereas Bcl-2 was downregulated in a time-dependent manner.ConclusionsPCS and PCG promote intrahepatic inflammation and BEC apoptosis, suggesting that gut microbial metabolites may contribute to hepatobiliary immune injury. 1. Introduction Primary biliary cholangitis (PBC) is an autoimmune liver disease with marked female predominance and substantial geographic variability, with a reported prevalence ranging from 19 to 402 cases per million individuals. 1 Its development is thought to result from a combination of environmental triggers, genetic susceptibility, and epigenetic modifications.2-4 PBC is characterized by chronic intrahepatic cholestasis and progressive non-suppurative inflammation of the medium-to-small intrahepatic bile ducts. 4 The pathophysiology involves the loss of immune tolerance to biliary epithelial cells, cholestasis, liver fibrosis, and ultimately cirrhosis. 5 Major clinical challenges include limited therapeutic options and considerable heterogeneity in disease presentation and progression. 6 Currently, no approved disease-modifying treatment exists other than liver transplantation, although several emerging agents have shown promising results in clinical trials.6,7 Therefore, identifying novel biomarkers and mechanisms that contribute to PBC progression is crucial for improving therapeutic strategies. The gut microbiome constitutes a complex and diverse ecosystem that plays an essential role in human health and disease. 8 Growing evidence indicates that gut microbiota influence PBC through the production of various metabolites and bioactive small molecules.9-11 Notably, loss of beneficial commensal Clostridium species has been observed in patients with PBC, and reduced Faecalibacterium abundance may predict poor long-term outcomes. 11 Moreover, recent findings suggest that the abundance of Clostridium correlates with patients’ response to ursodeoxycholic acid (UDCA) therapy. 12 Gut microbiota also modulates bile acid metabolism, composition, and pool size, thereby affecting intestinal microbial diversity and homeostasis. 13 Disruption of bile composition has been proposed as an initial driver of biliary epithelial injury in PBC. 14 Together, these observations imply that alterations in gut microbiota and microbial-derived metabolites may contribute to persistent intrahepatic inflammation in PBC. P-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG) are phenolic metabolites generated from aromatic amino acids by intestinal Clostridium species. 15 Dietary and endogenous proteins are degraded into aromatic amino acids such as tyrosine and phenylalanine, which are fermented by Clostridium into p-creso. 16 The liver subsequently conjugates p-cresol into PCS and PCG, which are then excreted via the urinary system. 17 PCS and PCG are recognized as uremic toxins with pro-apoptotic and pro-inflammatory properties in several disease settings.18-20 However, their roles in the liver particularly in regulating apoptosis and inflammation remain poorly understood. In the present study, we aimed to investigate the pro-apoptotic and pro-inflammatory effects of PCS and PCG both in vitro and in vivo. 2. Materials and Methods 2.1. Cell Line and Cell Culture Human biliary epithelial cell (HIBEpiCs, HTX2317, OTWO, China) were obtained from Otwo Biotech (Shenzhen, China) and cultured in RPMI 1640 medium (SH30809.01; Hyclone™, USA), supplemented with 1% (v/v) penicillin-streptomycin solution (SV30010; Hyclone™, USA) and 10% (v/v) fetal bovine serum (FBS, 10099-141; Gibco™, Australia) at 37°C in a 5% CO2 humidified atmosphere. When the cells reached 85% confluence, they were detached using 0.25% trypsin and passaged every 3 days. The third-passage cells, during the exponential growth phase, were selected for subsequent experiments. 2.2. Cell Treatment A total of 3,000 cells were seeded overnight into 12-well plates (712001; NEST, China) in RPMI 1640 supplemented with 10% FBS. The cells were then cultured in serum-free medium for 24 hours. Following this, gradient concentrations of p-Cresyl sulfate (PCS, A8895; APExBIO, USA) at 100, 200, and 500 µg/mL, and p-Cresyl glucuronide (PCG, C782005; APExBIO, USA) at 10, 25, and 100 µg/mL were added to the cells. Equimolar phosphate-buffered saline (PBS) was used as the vehicle control. Morphological changes were observed using an inverted microscope (CKX53; Olympus, Japan). 2.3. Cell Apoptosis Analysis Apoptosis in HIBEpiCs treated with PCS and PCG was assessed by flow cytometry using a Fluorescein Isothiocyanate (FITC) Annexin V/propidium iodide (PI) apoptosis detection kit (640914; BioLegend, USA) according to the manufacturer’s protocol. A total of 5 x 104 cells were seeded in 6-well plates incubated for 24 hours in serum-free medium. After incubation, cells were treated with 200 µg/mL of PCS or 25 µg/mL of PCG for an additional 24 hours. Cells were then collected, washed with cold sterile PBS, pelleted, counted (for cell number determinations), and resuspended in 1X annexin-binding buffer at a concentration of 1 x 105 cells/100 µL. The cells were incubated for 15 minutes with FITC Annexin V and PI (100 µg/mL), then further diluted with 300 µL of 1X annexin-binding buffer. The stained cells were analyzed using a flow cytometer (Partec GmbH, Muenster, Germany), with fluorescence emission measured at 530 nm (FL1) and > 575 nm (FL3). Single-color stains for FITC Annexin V and PI, as well as unstained cells, were included in all experiments as positive and negative controls. 2.4. Animals Animal experiments were conducted and reported in accordance with the ARRIVE 2.0 guidelines. Animal experiments were conducted to investigate the in vivo effects of PCS and PCG, and were approved by the Ethics Committee of Kunming Medical University (Approval number: KMMU2020190). A total of 27 female C57BL/6 mice (4-6 weeks old) were randomly assigned to one control group and eight treatment groups, including PCS-treated mice (1, 2, 3, and 4 weeks) and PCG-treated mice (1, 2, 3, and 4 weeks), with three mice in each group. The experimental groups received intraperitoneal injections of 100 µL of PCS or PCG (10 mg/kg body weight, 100 μL per injection), while the control group received equal volume of 1× PBS. The dose was selected based on our previous study and published reports demonstrating measurable biological effects without overt systemic toxicity. 15 All mice were injected twice daily. Mice in the PCS and PCG groups were euthanized after 1, 2, 3, or 4 weeks of treatment according to their assigned groups. Control mice were maintained under identical conditions and euthanized at the end of the experimental period. Serum and liver tissues were collected for subsequent analyses. 2.5. Hematoxylin and Eosin (H & E) Staining Fresh liver tissues were immediately fixed in 10% formalin, embedded in paraffin, and sectioned into 5-μm slices for hematoxylin and eosin (H & E) staining (G1120; Solarbio Life Science, Beijing, China). After deparaffinization, rehydration, antigen retrieval, and sealing, the tissue sections underwent color-based staining. The severity of liver disease was assessed based on the infiltration of inflammation-related cells in the epithelial tissue. 2.6. Enzyme-Linked Immunosorbent Assay (ELISA) To quantify the secretion of cytokines, the Mouse IFN-γ ELISA Kit (JL18210; Jianglai Biological Technology Co. Ltd., Shanghai, China) and the Mouse TGF-β ELISA Kit (JL13959; Jianglai Biological Co. Ltd.) were used. Mice serum, cryopreserved at -80°C, was thawed and utilized for analysis. The procedures were carried out according to the manufacturer’s instructions. 2.7. Western Blot Analysis Total protein was extracted with RAPI lysis buffer (Beyotime, China) according to the manufacturer’s instruments. A total of 100 μg of protein was separated using a 10% SDS-PAGE Gel Kit (P1200; Solarbio) and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were then blocked with a 5% solution of non-fat milk powder in Tris-buffered saline containing Tween-20 (TBST, T8220-100; Solarbio) and incubated at room temperature for approximately 2 hours. Subsequently, the membranes were incubated overnight at 4°C with primary antibodies, including rabbit polyclonal anti-Caspase-3 (1:1000, 19677-1-AP; Proteintech, Rosemont, IL, USA), rabbit polyclonal anti-BAX (1:1000, 50599-2-Ig; Proteintech), and rabbit polyclonal anti-Bcl-2 (1:1000, 16026-1-AP; Proteintech). After primary antibody incubation, the membranes were incubated with Goat Anti-Rabbit IgG H&L horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000, ab6721; Abcam) in 5% (w/v) non-fat milk in TBST for 2 hours at room temperature. The membranes were then washed with TBST, and protein bands were visualized using a chemiluminescence reagent (ECL, BL520A; Biosharp, Anhui, China). Finally, the images were quantified using ImageJ analysis software (https://www.imagej.net). 2.8. Statistical Analysis Statistical analyses in this study were performed using GraphPad version 9.0 (GraphPad Software Inc., La Jolla, CA, USA). All values were presented as mean ± standard deviation (SD) from at least three independent experiments. The differences between multiple groups were performed using one-way analysis of variance (ANOVA). P-value < 0.05 was considered as statistical significance. 3. Results 3.1. P-Cresyl Sulfate (PCS) and p-Cresyl Glucuronide (PCG) Promotes Biliary Epithelial Cell Apoptosis in Vitro To investigate the effects of p-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG), increasing concentration of PCS (100, 200, and 500 µg/mL) and PCG (10, 25, and 100 µg/mL) were incubated with HIBEpiCs. As shown in Figure 1A, cells in the control group exhibited a larger cell volume, thinner cytoplasm, and pseudopod-like protrusions. In contrast, after treatment with various concentrations of PCS or PCG, cell volume decreased, cells adopted a long spindle shape, and pseudopod-like protrusions were absent. Additionally, we observed that PCS and PCG promotes cell apoptosis compared to the control group (Figure 1B and C). These results suggest that PCS and PCG induce increased cell apoptosis.Figure 1.P-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG) promotes biliary epithelial cell apoptosis in vitro.(A) Morphological changes of HIBEpiCs after treatment with different concentrations of PCS (100, 200, 500 µg/mL) or PCG (10, 25, 100 µg/mL). (B) Representative flow cytometry analysis of cell apoptosis after treatment with 200 µg/mL PCS or 25 µg/mL PCG. (C) Quantification of apoptosis as the percentage of apoptotic cells. Data are presented as mean ± SD. ***p < 0.0001 versus control P-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG) promotes biliary epithelial cell apoptosis in vitro. (A) Morphological changes of HIBEpiCs after treatment with different concentrations of PCS (100, 200, 500 µg/mL) or PCG (10, 25, 100 µg/mL). (B) Representative flow cytometry analysis of cell apoptosis after treatment with 200 µg/mL PCS or 25 µg/mL PCG. (C) Quantification of apoptosis as the percentage of apoptotic cells. Data are presented as mean ± SD. ***p < 0.0001 versus control 3.2. PCS and PCG Promotes Liver Damage in Vivo We further investigated the effects of PCS and PCG on the liver in vivo. Mice were intraperitoneally injected with PCS (10 mg/kg) or PCG (10 mg/kg) for 1, 2, 3, and 4 weeks, respectively (Figure 2A). PCS and PCG treatment resulted in inflammatory cell infiltration in the portal area (Figure 2B and C). Specifically, lymphocyte infiltration was more pronounced in PCS-treated mice, while it was relatively mild in the PCG group. Overall, the degree of inflammation in both PCS and PCG groups increased with the duration of treatment (Figure 2B and C). These findings indicate that PCS and PCG may promote liver damage by enhancing inflammatory responses.Figure 2.PCS and PCG promotes liver damage in vivo.(A) Schematic diagram of experimental design: mice were intraperitoneally injected with PCS, PCG (10 mg/kg, n = 3 per group), or PBS (equal volume, n = 3). (B) and (C) Representative H&E staining showing liver histopathology after PCS, PCG, or PBS treatment PCS and PCG promotes liver damage in vivo. (A) Schematic diagram of experimental design: mice were intraperitoneally injected with PCS, PCG (10 mg/kg, n = 3 per group), or PBS (equal volume, n = 3). (B) and (C) Representative H&E staining showing liver histopathology after PCS, PCG, or PBS treatment 3.3. PCS and PCG Promotes Intrahepatic Inflammation in Vivo To determine whether PCS and PCG trigger inflammation, we measured serum levels of IFN-γ and TGF-β following PCS and PCG treatment. We observed both PCS (Figure 3A and B) and PCG (Figure 3C and D) caused a time-dependent increase in IFN-γ and TGF-β levels, although not all time points reached statistical significance. These results suggest that PCS and PCG may promote inflammatory responses, contributing to liver damage.Figure 3.PCS and PCG promotes intrahepatic inflammation in vivo.(A and B) Serum levels of IFN-γ and TGF-β in mice treated with PCS for 1, 2, 3, and 4 weeks. (C and D) Serum levels of IFN-γ and TGF-β in mice treated with PCG for 1, 2, 3, and 4 weeks. Data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 PCS and PCG promotes intrahepatic inflammation in vivo. (A and B) Serum levels of IFN-γ and TGF-β in mice treated with PCS for 1, 2, 3, and 4 weeks. (C and D) Serum levels of IFN-γ and TGF-β in mice treated with PCG for 1, 2, 3, and 4 weeks. Data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 3.4. PCS and PCG Promotes Cell Apoptosis in Vivo We next examined whether PCS and PCG induce apoptosis in vivo. Western blot analysis showed that the levels of the pro-apoptotic proteins Caspase-3 and Bax increased, while the expression of the anti-apoptotic protein Bcl-2 decreased in a time-dependent manner following PCS (Figure 4A-D) and PCG treatment (Figure 4E-H). These results suggest that PCS and PCG may promote hepatocyte apoptosis to contribute liver damage.Figure 4.PCS and PCG promotes cell apoptosis in vivo.(A and E) Representative Western blots showing increased Bax and caspase-3 and decreased Bcl-2 in liver tissue after PCS (A) or PCG (E) treatment (n = 3). (B-D, F-H) Quantification of pro-apoptotic proteins (Bax, caspase-3) and anti-apoptotic protein (Bcl-2) relative to control. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 PCS and PCG promotes cell apoptosis in vivo. (A and E) Representative Western blots showing increased Bax and caspase-3 and decreased Bcl-2 in liver tissue after PCS (A) or PCG (E) treatment (n = 3). (B-D, F-H) Quantification of pro-apoptotic proteins (Bax, caspase-3) and anti-apoptotic protein (Bcl-2) relative to control. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 4. Discussion Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small intrahepatic bile ducts. Increasing evidence links PBC to metabolic dysregulation, altered bile acid homeostasis, and gut microbiota-derived metabolites.21-23 Of particular interest is the enrichment of Clostridia species and their metabolites in PBC, which may influence disease progression and therapeutic response.12,24 Among these metabolites, p-cresyl sulfate (PCS) and p-cresyl glucuronide (PCG) are well-characterized uremic toxins derived from microbial metabolism of aromatic amino acids and hepatic conjugation.18-20,25 Interestingly, Fu et al previously reported that PCS alleviated hepatic inflammation in a murine PBC model by regulating Kupffer cell activity, 15 whereas our study demonstrated pro-inflammatory and pro-apoptotic effects of PCS and PCG. This apparent discrepancy may reflect differences in experimental context rather than truly conflicting biological effects. The previous study investigated Kupffer cell-mediated immune regulation within an established autoimmune cholangitis model, whereas our work focused on the direct impact of exogenous PCS and PCG exposure on biliary epithelial cells and liver tissue. Moreover, the biological activity of PCS is likely context-dependent and influenced by concentration, exposure duration, disease stage, and cellular target. Thus, PCS may exert immunomodulatory effects under certain pathological conditions while promoting inflammation, oxidative stress, and apoptosis under others. Collectively, these findings suggest that PCS may possess multifaceted and cell-specific functions during hepatobiliary disease progression. In this study, we demonstrate that both PCS and PCG induce biliary epithelial cell apoptosis in vitro and promote intrahepatic inflammation and liver injury in vivo. These findings suggest that microbial phenolic metabolites may contribute to cholangiocyte injury and hepatic inflammation, thereby linking gut dysbiosis to pathological changes observed in PBC (Figure 5).Figure 5.Proposed mechanism of PCS and PCG-induced liver injury.Schematic illustrating PCS and PCG promote intrahepatic inflammation and biliary epithelial cell apoptosis, contributing to liver injury Proposed mechanism of PCS and PCG-induced liver injury. Schematic illustrating PCS and PCG promote intrahepatic inflammation and biliary epithelial cell apoptosis, contributing to liver injury Clinical and metabolomic data support the biological plausibility of this model. Patients with PBC frequently present with elevated serum Phenylalanine and Tyrosine levels and altered gut microbiota composition, particularly enrichment of Clostridium species capable of generating p-cresol precursors. 26 Increased microbial production of aromatic metabolites, together with impaired biliary excretion in cholestatic states, may enhance systemic accumulation of PCS/PCG. 27 Consistent with this concept, chronic administration of PCS and PCG in our study resulted in inflammatory infiltration, cytokine elevation, and activation of apoptotic pathways, supporting a functional role for these metabolites in liver injury. It is important to emphasize that Clostridium is a highly heterogeneous bacterial genus. Certain commensal Clostridium species contribute to immune tolerance, short-chain fatty acid production, and maintenance of intestinal homeostasis, whereas other species participate in p-cresol production from aromatic amino acids. Consequently, the depletion of beneficial Clostridium populations and the increased generation of p-cresol-derived metabolites are not mutually exclusive phenomena. Instead, both alterations may occur simultaneously during PBC-associated dysbiosis and contribute to disease progression through distinct mechanisms. Mechanistically, we observed that PCS and PCG elevated serum IFN-γ and TGF-β levels in a time-dependent manner and promoted inflammatory cell infiltration in the portal areas. These findings are consistent with previous reports demonstrating that PCS activates NADPH oxidase, enhances reactive oxygen species (ROS) generation, and stimulates pro-inflammatory signaling in renal tubular cells, endothelial cells, and macrophages.28-30 Although not all time points reached statistical significance, the overall temporal trend supports the notion that chronic exposure to PCS and PCG may progressively establish a pro-inflammatory hepatic microenvironment. The observed elevation of IFN-γ and TGF-β is also biologically relevant to cholangitis pathogenesis. IFN-γ contributes to hepatic immune activation by enhancing the cytotoxic functions of NK cells and CD8+ T cells, whereas TGF-β plays central roles in immune regulation, tissue remodeling, and fibrosis development.31-36 Although pCS induced slightly higher cytokine responses than pCG, the differences were not statistically significant, potentially due to sample size limitations or solute-specific physicochemical differences; for example, pCS generate ROS while pCG can potentiate pCS-mediated inflammatory effects without directly inducing oxidative stress. 37 Together, these mechanisms provide a coherent framework linking gut microbial metabolites to hepatic immune activation. Apoptosis represents a second critical injury mechanism. We observed increased hepatic expression of caspase-3 and Bax, alongside reduced Bcl-2, indicating activation of intrinsic apoptotic pathways. This is consistent with studies demonstrating caspase-dependent apoptosis and S-phase arrest induced by PCS in renal and endothelial cells.25,30 Given that cholangiocyte apoptosis is a hallmark of PBC progression, our results suggest that PCS and PCG may contribute directly to biliary epithelial cell loss and disease progression. Beyond inflammation and apoptosis, PCS and PCG have been reported to exert broader immunomodulatory effects, including suppression of IL-12 production, 38 inhibition of B-cell progenitor proliferation, and impairment of antigen processing. 39 These immunological alterations may further disrupt hepatic immune homeostasis, although their relevance in cholestatic settings warrants further investigation. Several limitations should be considered when interpreting our findings. First, endogenous PCS and PCG concentrations were not measured in patients with PBC, limiting direct clinical extrapolation. Second, although inflammation and apoptosis were identified as major biological responses, the precise molecular mechanisms remain incompletely defined. Future studies should investigate the potential involvement of ROS generation, AhR signaling, TLR4 activation, bile acid signaling pathways, and microbiota-host interactions. Third, the liver injury observed in our model was relatively mild, suggesting that longer exposure periods, higher metabolite concentrations, or additional disease-promoting factors may be required to better mimic human PBC. Finally, only a single PBS-treated control group was included and euthanized at the end of the study period, and time-matched control groups were not established at each intermediate time point. Although all animals were maintained under identical experimental conditions, this design may limit interpretation of temporal changes and should be considered when evaluating the results. 5. Conclusion In summary, PCS and PCG promote hepatic inflammation and apoptosis both in vitro and in vivo, providing evidence that gut microbiota-derived phenolic metabolites may contribute to cholestatic liver injury. These findings support a potential role for PCS and PCG as mediators linking gut dysbiosis to PBC pathogenesis and highlight microbial metabolite-targeted interventions as a promising direction for future therapeutic development. Supplemental Material Supplemental Material - Clostridium-Derived p-Cresyl Metabolites Induce Inflammation and Apoptosis in Biliary Epithelial Cells Supplemental Material for Clostridium-Derived p-Cresyl Metabolites Induce Inflammation and Apoptosis in Biliary Epithelial Cells by Haiyan Yu, Haiyan Fu, Jiamin Xu, Yina Yang, Xin Ai, Rongfang Tu, Weimin Bao, Yingmei Tang in Cancer Informatics